Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DX-DRG-C01
- Development stage
- Preclinical
- Lead developer
- Dx&Vx
- Modality
- Peptides, Small Molecules
01
Overview
DX-DRG-C01 is a Glucagon-like peptide 1 receptor (GLP-1R) agonist currently under development by Dx&Vx (formerly MG Med) for the treatment of obesity. The drug is designed to activate the GLP-1 receptor, mimicking the effects of the natural incretin hormone GLP-1, which plays a crucial role in appetite suppression and glucose-dependent insulin secretion. By targeting GLP-1R, DX-DRG-C01 aims to induce weight loss and improve metabolic health. It is positioned within the company's obesity treatment pipeline and is currently in the preclinical stage of development.
- Other names
- GLP-1 Receptor AgonistGLP1 Receptor AgonistGLP 1 Receptor Agonist
02
Targets
Beyond the preview
Go deeper on DX-DRG-C01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DX-DRG-C01.